The University of Edinburgh and FUJIFILM Diosynth Biotechnologies UK (FDB) are leading an £8.7 million, five-year research collaboration to develop more cost-effective ways to make modern antibody-based medicines.
Researchers have discovered that a class of drugs being developed to treat cancer can also help prompt liver regeneration after severe injury, raising hopes of a new treatment that might help some patients avoid a liver transplant.